MM Genetics

MM Genetics, established in Spain, specializes in developing and releasing cannabidiol-focused cannabis cultivars to the market. The company partners with renowned breeders and cannabis specialists throughout Europe, resulting in impressive genetics such as Candida-CD1, which features a remarkable 20:1 cannabidiol-to-tetrahydrocannabinol profile. Working alongside medical patients and cannabis communities has informed MM Genetics' understanding that therapeutic cannabis applications target relief of particular health conditions. The company's portfolio includes multiple cannabidiol-rich strains with numerous accolades, including recognition as the top CBD variety at Spannabis 2017. These cultivars address a wide spectrum of conditions including chronic pain, inflammatory responses, seizure disorders, convulsive episodes, digestive system issues, nausea, vomiting, dermatological conditions, microbial infections, anxiety disorders, depression, and abnormal cellular growth among others. Medical Marijuana Genetics continues advancing its breeding efforts to identify and develop strains containing significant levels of cannabinoids and aromatic terpene compounds.